In their article, Howlader et al. found 73% Luminal A tumours, defined as HR+/HER2- tumours (versus 77.6% in our study), 12% triple-negative tumours (versus 10.7% in our study), 5% HER 2 positive tumours with negative hormone receptors (versus 4.3%) and 10% HR+/HER2 + tumours (versus 7.3% in our study). This evidence concerns the gene ERBB2 and neoplasm.